127 related articles for article (PubMed ID: 10623796)
1. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs.
Hiroishi K; Tüting T; Lotze MT
J Immunol; 2000 Jan; 164(2):567-72. PubMed ID: 10623796
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction.
Eguchi J; Hiroishi K; Ishii S; Baba T; Matsumura T; Hiraide A; Okada H; Imawari M
Gene Ther; 2005 May; 12(9):733-41. PubMed ID: 15772692
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
6. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
[TBL] [Abstract][Full Text] [Related]
7. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
8. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells.
Luo L; Chapoval AI; Flies DB; Zhu G; Hirano F; Wang S; Lau JS; Dong H; Tamada K; Flies AS; Liu Y; Chen L
J Immunol; 2004 Nov; 173(9):5445-50. PubMed ID: 15494491
[TBL] [Abstract][Full Text] [Related]
10. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
13. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses.
Santra S; Barouch DH; Jackson SS; Kuroda MJ; Schmitz JE; Lifton MA; Sharpe AH; Letvin NL
J Immunol; 2000 Dec; 165(12):6791-5. PubMed ID: 11120800
[TBL] [Abstract][Full Text] [Related]
14. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
[TBL] [Abstract][Full Text] [Related]
15. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells stimulated with cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively reduce outgrowth of established tumors in vivo.
Hiraide A; Hiroishi K; Eguchi J; Ishii S; Doi H; Imawari M
Cancer Sci; 2008 Aug; 99(8):1663-9. PubMed ID: 18754881
[TBL] [Abstract][Full Text] [Related]
17. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
20. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
Chen L; McGowan P; Ashe S; Johnston J; Li Y; Hellström I; Hellström KE
J Exp Med; 1994 Feb; 179(2):523-32. PubMed ID: 7507508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
